vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
Reddit, Inc.的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.6倍（$663.0M vs $406.6M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 30.8%，领先29.7%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 69.0%），Reddit, Inc.自由现金流更多（$311.0M vs $291.2M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 53.6%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
BCRX vs RDDT — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $663.0M |
| 净利润 | $245.8M | $204.0M |
| 毛利率 | 97.7% | 100.0% |
| 营业利润率 | 64.0% | 0.0% |
| 净利率 | 60.5% | 30.8% |
| 营收同比 | 209.1% | 69.0% |
| 净利润同比 | 1017.5% | 680.0% |
| 每股收益（稀释后） | $1.13 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $663.0M | ||
| Q4 25 | $406.6M | $725.6M | ||
| Q3 25 | $159.4M | $584.9M | ||
| Q2 25 | $163.4M | $499.6M | ||
| Q1 25 | $145.5M | $392.4M | ||
| Q4 24 | $131.5M | $427.7M | ||
| Q3 24 | $117.1M | $348.4M | ||
| Q2 24 | $109.3M | $281.2M |
| Q1 26 | — | $204.0M | ||
| Q4 25 | $245.8M | $251.6M | ||
| Q3 25 | $12.9M | $162.7M | ||
| Q2 25 | $5.1M | $89.3M | ||
| Q1 25 | $32.0K | $26.2M | ||
| Q4 24 | $-26.8M | $71.0M | ||
| Q3 24 | $-14.0M | $29.9M | ||
| Q2 24 | $-12.7M | $-10.1M |
| Q1 26 | — | 100.0% | ||
| Q4 25 | 97.7% | 91.9% | ||
| Q3 25 | 98.6% | 91.0% | ||
| Q2 25 | 98.3% | 90.8% | ||
| Q1 25 | 96.9% | 90.5% | ||
| Q4 24 | 95.4% | 92.6% | ||
| Q3 24 | 97.3% | 90.1% | ||
| Q2 24 | 98.4% | 89.5% |
| Q1 26 | — | 0.0% | ||
| Q4 25 | 64.0% | 31.9% | ||
| Q3 25 | 18.6% | 23.7% | ||
| Q2 25 | 18.2% | 13.6% | ||
| Q1 25 | 14.6% | 1.0% | ||
| Q4 24 | -3.4% | 12.4% | ||
| Q3 24 | 6.6% | 2.0% | ||
| Q2 24 | 8.0% | -11.0% |
| Q1 26 | — | 30.8% | ||
| Q4 25 | 60.5% | 34.7% | ||
| Q3 25 | 8.1% | 27.8% | ||
| Q2 25 | 3.1% | 17.9% | ||
| Q1 25 | 0.0% | 6.7% | ||
| Q4 24 | -20.4% | 16.6% | ||
| Q3 24 | -12.0% | 8.6% | ||
| Q2 24 | -11.6% | -3.6% |
| Q1 26 | — | $1.01 | ||
| Q4 25 | $1.13 | $1.24 | ||
| Q3 25 | $0.06 | $0.80 | ||
| Q2 25 | $0.02 | $0.45 | ||
| Q1 25 | $0.00 | $0.13 | ||
| Q4 24 | $-0.13 | $4.76 | ||
| Q3 24 | $-0.07 | $0.16 | ||
| Q2 24 | $-0.06 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $3.2B |
| 总资产 | $514.2M | $3.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $1.4B | ||
| Q4 25 | $274.7M | $953.6M | ||
| Q3 25 | $212.9M | $911.7M | ||
| Q2 25 | $260.0M | $734.1M | ||
| Q1 25 | $295.1M | $635.7M | ||
| Q4 24 | $320.9M | $562.1M | ||
| Q3 24 | $96.8M | $515.9M | ||
| Q2 24 | $78.4M | $468.0M |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $-119.2M | $2.9B | ||
| Q3 25 | $-387.9M | $2.6B | ||
| Q2 25 | $-421.6M | $2.4B | ||
| Q1 25 | $-451.9M | $2.2B | ||
| Q4 24 | $-475.9M | $2.1B | ||
| Q3 24 | $-468.6M | $2.0B | ||
| Q2 24 | $-475.6M | $1.9B |
| Q1 26 | — | $3.5B | ||
| Q4 25 | $514.2M | $3.2B | ||
| Q3 25 | $446.4M | $2.9B | ||
| Q2 25 | $457.2M | $2.6B | ||
| Q1 25 | $480.0M | $2.4B | ||
| Q4 24 | $490.4M | $2.3B | ||
| Q3 24 | $491.3M | $2.2B | ||
| Q2 24 | $472.4M | $2.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | — |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $311.0M |
| 自由现金流率自由现金流/营收 | 71.6% | 46.9% |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 1.19× | — |
| 过去12个月自由现金流最近4个季度 | $344.9M | $868.6M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $266.8M | ||
| Q3 25 | $41.6M | $185.2M | ||
| Q2 25 | $41.3M | $111.3M | ||
| Q1 25 | $-27.5M | $127.6M | ||
| Q4 24 | $-5.2M | $90.0M | ||
| Q3 24 | $8.2M | $71.6M | ||
| Q2 24 | $-1.4M | $28.4M |
| Q1 26 | — | $311.0M | ||
| Q4 25 | $291.2M | $263.6M | ||
| Q3 25 | $40.3M | $183.1M | ||
| Q2 25 | $41.1M | $110.8M | ||
| Q1 25 | $-27.7M | $126.6M | ||
| Q4 24 | $-5.9M | $89.2M | ||
| Q3 24 | $8.2M | $70.3M | ||
| Q2 24 | $-1.5M | $27.2M |
| Q1 26 | — | 46.9% | ||
| Q4 25 | 71.6% | 36.3% | ||
| Q3 25 | 25.3% | 31.3% | ||
| Q2 25 | 25.2% | 22.2% | ||
| Q1 25 | -19.0% | 32.3% | ||
| Q4 24 | -4.5% | 20.8% | ||
| Q3 24 | 7.0% | 20.2% | ||
| Q2 24 | -1.4% | 9.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 0.4% | ||
| Q3 25 | 0.8% | 0.4% | ||
| Q2 25 | 0.1% | 0.1% | ||
| Q1 25 | 0.1% | 0.2% | ||
| Q4 24 | 0.5% | 0.2% | ||
| Q3 24 | 0.1% | 0.4% | ||
| Q2 24 | 0.1% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 1.06× | ||
| Q3 25 | 3.23× | 1.14× | ||
| Q2 25 | 8.12× | 1.25× | ||
| Q1 25 | -859.91× | 4.88× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 2.40× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
